Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019)

Aquestive Therapeutics (AQST) recorded quarterly Asset Writedowns and Impairment of $6000.0 in Q3 2019, down 75.0% quarter-over-quarter from $24000.0 in Q2 2019, and down 85.71% on a YoY basis from $42000.0 in Q3 2018.

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019) Analysis & Trends

Aquestive Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $6000.0 for Q3 2019.

  • In Q3 2019, Asset Writedowns and Impairment fell 85.71% year-over-year to $6000.0; the TTM figure through Sep 2019 stood at $16000.0 (changed N/A YoY), while the FY2018 annual figure was $53000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment was $6000.0 for Q3 2019 at Aquestive Therapeutics, down from $24000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $42000.0 in Q3 2018 to a low of -$20000.0 in Q4 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn
10 Aquestive Therapeutics 487.99 Mn 377.25 Mn 10.98 Mn

Historic Data

Download Data
DateValue
Sep 30, 2019 6,000.00
Sep 30, 2019 6,000.00
Jun 30, 2019 24,000.00
Jun 30, 2019 24,000.00
Mar 31, 2019 6,000.00
Mar 31, 2019 6,000.00
Dec 31, 2018 -20,000.00
Dec 31, 2018 -20,000.00
Sep 30, 2018 42,000.00
Sep 30, 2018 42,000.00